Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 9943 results found since Jan 2013.
Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study
CONCLUSIONS: Delayed treatment approaching 2 months was observed in 10% of the population. The rising temporal trend in TTT may be attributed to the increasing shift toward neoadjuvant CT/RT in early-stage PDAC and/or the increasing use of tissue biopsy prior to surgery.PMID:37624518 | DOI:10.1245/s10434-023-14221-9
Source: Ann Oncol - August 25, 2023 Category: Cancer & Oncology Authors: Kavin Sugumar Jonathan J Hue Shreya Gupta Mohamedraed Elshami Luke D Rothermel Lee M Ocuin John B Ammori Jeffrey M Hardacre Jordan M Winter Source Type: research
ASO Visual Abstract: Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment
Ann Surg Oncol. 2023 Aug 25. doi: 10.1245/s10434-023-14226-4. Online ahead of print.NO ABSTRACTPMID:37626250 | DOI:10.1245/s10434-023-14226-4
Source: Ann Oncol - August 25, 2023 Category: Cancer & Oncology Authors: Kirithiga Ramalingam Elle Clelland Harriet Rothschild Firdows Mujir Helena Record Mandeep Kaur Rita A Mukhtar Source Type: research
Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study
CONCLUSIONS: Delayed treatment approaching 2 months was observed in 10% of the population. The rising temporal trend in TTT may be attributed to the increasing shift toward neoadjuvant CT/RT in early-stage PDAC and/or the increasing use of tissue biopsy prior to surgery.PMID:37624518 | DOI:10.1245/s10434-023-14221-9
Source: Ann Oncol - August 25, 2023 Category: Cancer & Oncology Authors: Kavin Sugumar Jonathan J Hue Shreya Gupta Mohamedraed Elshami Luke D Rothermel Lee M Ocuin John B Ammori Jeffrey M Hardacre Jordan M Winter Source Type: research
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
CONCLUSIONS: Incorporation of atezolizumab into standard therapy for newly diagnosed ovarian cancer does not significantly improve efficacy or impose additional treatment burden for patients.CLINICALTRIALS: gov registration: NCT03038100.PMID:37625235 | DOI:10.1016/j.ygyno.2023.06.018
Source: Gynecologic Oncology - August 25, 2023 Category: Cancer & Oncology Authors: Sandro Pignata Michael Bookman Jalid Sehouli Austin Miller Richard T Penson Cagatay Taskiran Charles Anderson Sakari Hietanen Tashanna Myers Radoslaw Madry Lyndsay Willmott Alain Lortholary Jessica Thomes-Pepin Carol Aghajanian Carolyn McCourt Ashley Stuc Source Type: research
Management of advanced metacarpal aneurysmal cysts: surgical technique
We describe a technique involving segmental bone resection and structural iliac graft reconstruction with carpo-metacarpal plate arthrodesis, for the management of advanced ABC involving the base of the metacarpals. The radio-clinical results of two patients operated on using this technique are presented, at 18 and 36 months. At the last follow-up, the results showed a QDASH of 15 and 10, and a PRWE of 9 and 11. Satisfaction was 10/10 in both cases. Grasp strength was 25 kg and 42 kg versus 28 kg and 40 kg on the opposite side. Pinch strength was 6 kg and 11 kg versus 7 kg and 10 kg. Metacarpophalangeal flexion was 80° an...
Source: Hand Surgery - August 25, 2023 Category: Surgery Authors: Thomas Daoulas Olivier Bozon Michel Chammas Bertrand Coulet Cyril Lazerges Source Type: research
Cancers, Vol. 15, Pages 4264: Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis
Conclusions: Resectable HER2-low BC had a better prognosis than HER2-zero BC. Among those who received adjuvant chemotherapy in the higher oncotype RS group, those with HER2-low tumors had better survival.
Source: Cancers - August 25, 2023 Category: Cancer & Oncology Authors: Arya Mariam Roy Changchuan Jiang Stuthi Perimbeti Lei Deng Charles L. Shapiro Shipra Gandhi Tags: Article Source Type: research
ADAMTS12 promotes oxaliplatin chemoresistance and angiogenesis in gastric cancer through VEGF upregulation
CONCLUSIONS: These findings suggest that ADAMTS12 can modulate signaling via the MAPK/VEGF axis in GC cells to enhance tumor cell resistance to oxaliplatin treatment under hypoxic and normoxic conditions. Elevated ADAMTS12 levels can additionally predict vascular abnormalities, worse survival outcomes, and chemoresistance in patients with GC.PMID:37619822 | DOI:10.1016/j.cellsig.2023.110866
Source: Cellular Signalling - August 24, 2023 Category: Cytology Authors: Yingming Jiang Jintuan Huang Zhenze Huang Weiyao Li Rongchang Tan Tuoyang Li Zijian Chen Xiaocheng Tang Yandong Zhao Jun Qiu Chujun Li Hao Chen Zuli Yang Source Type: research
ASO Video Abstract: Neoadjuvant Chemo-Immunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable NSCLC
Ann Surg Oncol. 2023 Aug 24. doi: 10.1245/s10434-023-14163-2. Online ahead of print.NO ABSTRACTPMID:37620528 | DOI:10.1245/s10434-023-14163-2
Source: Ann Oncol - August 24, 2023 Category: Cancer & Oncology Authors: Tianxiang Chen Zhengqi Cao Yingjia Sun Jia Huang Shengping Shen Yueping Jin Long Jiang Fengcai Wen Xiaochen Zhao Ding Zhang Yanan Chen Mengli Huang Hao Chen Shun Lu Ziming Li Source Type: research
Research Priorities in Prehabilitation for Patients Undergoing Cancer Surgery: An International Delphi Study
CONCLUSIONS: This collaborative international study identified the top 10 research priorities in prehabilitation for patients undergoing cancer surgery. The identified priorities inform research strategies, provide future directions for prehabilitation research, support resource allocation and enhance the prehabilitation evidence base in cancer patients undergoing surgery.PMID:37620526 | DOI:10.1245/s10434-023-14192-x
Source: Ann Oncol - August 24, 2023 Category: Cancer & Oncology Authors: Pratik Raichurkar Linda Denehy Michael Solomon Cherry Koh Neil Pillinger Sophie Hogan Kate McBride Sharon Carey Jenna Bartyn Nicholas Hirst Daniel Steffens Prehabilitation Expert Collaborative Source Type: research
ADAMTS12 promotes oxaliplatin chemoresistance and angiogenesis in gastric cancer through VEGF upregulation
CONCLUSIONS: These findings suggest that ADAMTS12 can modulate signaling via the MAPK/VEGF axis in GC cells to enhance tumor cell resistance to oxaliplatin treatment under hypoxic and normoxic conditions. Elevated ADAMTS12 levels can additionally predict vascular abnormalities, worse survival outcomes, and chemoresistance in patients with GC.PMID:37619822 | DOI:10.1016/j.cellsig.2023.110866
Source: Cellular Signalling - August 24, 2023 Category: Cytology Authors: Yingming Jiang Jintuan Huang Zhenze Huang Weiyao Li Rongchang Tan Tuoyang Li Zijian Chen Xiaocheng Tang Yandong Zhao Jun Qiu Chujun Li Hao Chen Zuli Yang Source Type: research
Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature
ConclusionsThe heterogeneity of the studies included in this systematic review precludes the drawing of any relevant conclusions regarding the application of imiquimod. Its efficacy in melanoma in situ and lentigo maligna melanoma has been demonstrated, but further evidence from controlled studies concerning the modalities is missing.
Source: Dermatology and Therapy - August 24, 2023 Category: Dermatology Source Type: research
Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer
CONCLUSIONS: Neoadjuvant dose-dense biweekly nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide was effective, especially in patients with triple-negative disease, and feasible with pegfilgrastim support.PMID:37609671 | DOI:10.1093/jjco/hyad112
Source: Clinical Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Akiko Matsumoto Hiromitsu Jinno Saki Naruse Yuka Isono Yuka Maeda Ayana Sato Miki Yamada Tatsuhiko Ikeda Yuko Sasajima Source Type: research
